Arabic Arabic English English French French German German
dark

Bristol Myers’ Opdivo Fails to Maintain Accelerated Approval in Liver Cancer

The U.S. FDA’s Oncologic Drugs Advisory Committee did not agree in a recent meeting to maintain the accelerated approval of Bristol Myers Squibb’s Opdivo (nivolumab) as a second-line treatment of hepatocellular carcinoma. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

CareCar Raises $3M to Expand Tech-enabled Benefit Manager Platform

Next Post

KIYATEC Announces Investment from Seae Ventures and Names Co-founder and Managing Partner Jason Robart to its Board of Directors

Related Posts
Total
0
Share